Refine
Has Fulltext
- yes (70) (remove)
Is part of the Bibliography
- yes (70)
Year of publication
Document Type
- Journal article (68)
- Report (2)
Language
- English (70)
Keywords
- ischemic stroke (11)
- B cells (5)
- multiple sclerosis (5)
- Medizin (4)
- acute ischemic stroke (4)
- factor XII (4)
- inflammation (4)
- traumatic brain injury (4)
- MS (3)
- Mice (3)
- closed head injury (3)
- expression (3)
- neurology (3)
- relapse (3)
- trial (3)
- EAE (2)
- ELISPOT (2)
- Inflammation (2)
- NEUROWIND (2)
- SHRSP (2)
- Schlaganfall (2)
- Stroke (2)
- astrocytoma (2)
- biomarker (2)
- biomarkers (2)
- blood pressure (2)
- blood-brain barrier (2)
- cerebral autoregulation (2)
- chronic cerebrovascular disease (2)
- colony-stimulating factor (2)
- contact-kinin system (2)
- generalized cerebral edema (2)
- immune cells (2)
- in vivo imaging (2)
- infarction (2)
- lymphocytes (2)
- mouse (2)
- neuroinflammation (2)
- neuroprotection (2)
- oxidative stress (2)
- platelets (2)
- predictive value (2)
- reversible posterior leukoencephalopathy syndrome (2)
- stroke (2)
- therapy (2)
- von Willebrand factor (2)
- 2 PM (1)
- Alemtuzumab (1)
- Alzheimer’s disease (1)
- Arterial water (1)
- Brain (1)
- C1-inhibitor (1)
- CD52 (1)
- CNS (1)
- COU254 (1)
- CSVD (1)
- Cardiac dysfunction| Brain natriuretic peptide (1)
- Cerebral small vessel disease (1)
- Cerebral-ischemia (1)
- Coefficient (1)
- Crespi effect (1)
- Cryolesion (1)
- ERK1/2 (1)
- Experimental brain trauma (1)
- Experimental stroke (1)
- FTY720 (1)
- FTY720-P (1)
- FXII (1)
- FXIIa inhibitor rHA-Infestin (1)
- Glatiramer acetate (1)
- Head-injury (1)
- Heart failure (1)
- Hemodynamic depression (1)
- IBA-1 (1)
- IDH (1)
- IL-15 (1)
- IntelliCage (1)
- Intravascular coagulation (1)
- Intravital imaging (1)
- Ischemia (1)
- Kaliumkanal (1)
- MGMT (1)
- MIC ligands (1)
- MRI (1)
- Magnetic-resonance (1)
- Maus (1)
- Model (1)
- Molecular-weight heparin (1)
- NADPH oxidase inhibitors (1)
- NADPH oxidases (NOX) (1)
- NKG2D (1)
- NKG2D ligands (1)
- NMO-IGG (1)
- NMR-Tomographie (1)
- Neurodegeneration (1)
- Neurologie (1)
- PCDHGC3 (1)
- PET (1)
- Perfusion (1)
- R-715 (1)
- RKIP (1)
- Rats (1)
- STAIR (1)
- Secondary traumatic brain damage (1)
- Sphingosine 1-Phosphate (1)
- Stim (1)
- T cell activation (1)
- TBI (1)
- TLO (1)
- TNF-α (1)
- TSPO (1)
- Thrombus (1)
- Thrombus formation (1)
- Troponin (1)
- Vasodilatator-stimuliertes Phosphoprotein (1)
- Vasodilator-Stimulated Phosphoprotein (1)
- Von-Willebrand-factor (1)
- WNT signaling (1)
- Wissenschaftlicher Nachwuchs (1)
- Zonula Occludens-1 (1)
- accuracy (1)
- acute management of stroke (1)
- acute neurology (1)
- acute stroke imaging (1)
- acute stroke management (1)
- acute stroke outcome (1)
- adherence (1)
- alias pilot trial (1)
- animal model (1)
- anti-aquaporin-4 antibody (1)
- antibodies (1)
- anticoagulants (1)
- aquaporin-4 autoantibodies (1)
- astrocyte (1)
- astrocytes (1)
- astrogliosis (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- autoimmunity (1)
- autoradiography (1)
- blood (1)
- blood coagulability (1)
- blood coagulation (1)
- bradykinin (1)
- brain (1)
- brain edema (1)
- cancer stem cells (1)
- cardiovascular disease (1)
- celiac disease (1)
- cerebral inflammation (1)
- cerebral ischemia (1)
- cerebral small vessel disease (1)
- cerebrospinal-fluid (1)
- cerebrovascular diseases (1)
- chronic kidney disease (1)
- coagulation (1)
- coagulation factor XIIa (1)
- contact activation system (1)
- cortical pathology (1)
- cutting edge (1)
- damage cool aid (1)
- darbepoetin alpha (1)
- demography (1)
- dendric cells (1)
- developmental signaling (1)
- diabetes mellitus (1)
- diffuse (1)
- dimethyl fumarate (1)
- disability (1)
- disease (1)
- disease-modifying therapy (1)
- echocardiography (1)
- edema (1)
- efficacy (1)
- ejection fraction (1)
- emulsions (1)
- endothelial cells (1)
- endothelin-1 (1)
- experimental autoimmune encephalomyelitis (1)
- experimental stroke (1)
- extensiv transverse myelitis (1)
- factor XI (1)
- feasibility (1)
- fingolimod (1)
- fluorine (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral ischemia (1)
- focal cerebral-ischemia (1)
- free radical scavenger (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- glycoprotein Ib (1)
- glycoprotein receptor Ib (1)
- guidelines (1)
- heart failure (1)
- hematopoietic (1)
- histology (1)
- human muscle-cells (1)
- hypercholesterolemia (1)
- idiopathic inflammatory myopathies (1)
- immune-response (1)
- immunoglobulin-G (1)
- immunohistochemistry (1)
- in-vivo (1)
- increased risk (1)
- injection site reactions; (1)
- interleukin-1 receptor antagonist (1)
- intractable hiccup (1)
- intravenous thrombolysis (1)
- ischemia (1)
- ischemic cascade (1)
- kallikrein–kinin system (1)
- kinin receptor (1)
- kinin receptors (1)
- lesions (1)
- leukocytes (1)
- lymphokine-activated killer (1)
- mRNA (1)
- macrophages (1)
- magnetic resonance imaging (1)
- matrix metalloproteinases (1)
- mechanical thrombectomy (1)
- mechanisms (1)
- meninges (1)
- mice (1)
- mice impact (1)
- microglia (1)
- microsphere/macrosphere (1)
- middle cerebral artery occlusion (1)
- mitochondria (1)
- monocytes (1)
- mouse model (1)
- myasthenia gravis (1)
- myeloid (1)
- natural history (1)
- natural killer cells (1)
- neurobehavioural deficits (1)
- neuroimmunology (1)
- neurons (1)
- neurorepair (1)
- non-VKA oral anticoagulants (1)
- novo renal transplantation (1)
- object recognition memory (1)
- occlusion (1)
- pathology section (1)
- permanent and transient middle cerebral artery occlusion (1)
- pharmacology (1)
- photothrombosis (1)
- placebo-controlled (1)
- point-of-care echocardiography (1)
- polymorphisms inflammation (1)
- polymyositis (1)
- prefrontal cortex (1)
- prevention (1)
- progenitor (1)
- protein (1)
- quality of life (1)
- randomized controlled trial (1)
- rat (1)
- rat brain microvascular endothelial cell culture (1)
- receptor (1)
- recurrence (1)
- regulatory T cells (1)
- relapsing multiple sclerosis (1)
- relapsing-remitting multiple sclerosis (1)
- scale (1)
- search filter (1)
- sex addiction (1)
- small vessel disease (1)
- stress (1)
- stroke therapy (1)
- stroke unit (1)
- subcutaneous injection (1)
- systems biology (1)
- systolic dysfunction (1)
- tMCAO (1)
- temozolomide (1)
- thrombo-inflammation (1)
- thromboembolic clot model (1)
- thromboembolic stroke (1)
- thromboinflammation (1)
- thrombosis (1)
- thrombus formation (1)
- tight junctions (1)
- tissue-plasminogen activator (1)
- transient ischemic attack (1)
- transient middle cerebral artery (1)
- transient middle cerebral artery occlusion (1)
- transient middle cerebral artery occlusion model (1)
- translation (1)
- translational research (1)
- translational stroke research (1)
- troponin (1)
- tumor immunity (1)
- vascular dementia (1)
- vascular permeability (1)
- vitamin K antagonists (1)
- warfarin (1)
- weight drop (1)
- β-APP (1)
Institute
- Neurologische Klinik und Poliklinik (61)
- Neurochirurgische Klinik und Poliklinik (12)
- Institut für Anatomie und Zellbiologie (9)
- Institut für Klinische Epidemiologie und Biometrie (6)
- Rudolf-Virchow-Zentrum (5)
- Medizinische Klinik und Poliklinik I (4)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Experimentelle Biomedizin (2)
- Pathologisches Institut (2)
Background and Purpose
In animal models, von Willebrand factor (VWF) is involved in thrombus formation and propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and chronic cerebrovascular disease (CCD).
Methods
A case–control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA.
Results
Patients with CCD (158±46%) had significantly higher VWF levels than HV (113±36%, P<0.001), but lower levels than AIS/TIA patients (200±95%, P<0.001). Age, sex, and stroke severity influenced VWF levels (P<0.05).
Conclusions
VWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for stroke severity, warranting further investigation.
BACKGROUND: Recently, members of the two-pore domain potassium channel family (K2P channels) could be shown to be involved in mechanisms contributing to neuronal damage after cerebral ischemia. K2P3.1-/- animals showed larger infarct volumes and a worse functional outcome following experimentally induced ischemic stroke. Here, we question the role of the closely related K2P channel K2P9.1. METHODS: We combine electrophysiological recordings in brain-slice preparations of wildtype and K2P9.1-/- mice with an in vivo model of cerebral ischemia (transient middle cerebral artery occlusion (tMCAO)) to depict a functional impact of K2P9.1 in stroke formation. RESULTS: Patch-clamp recordings reveal that currents mediated through K2P9.1 can be obtained in slice preparations of the dorsal lateral geniculate nucleus (dLGN) as a model of central nervous relay neurons. Current characteristics are indicative of K2P9.1 as they display an increase upon removal of extracellular divalent cations, an outward rectification and a reversal potential close to the potassium equilibrium potential. Lowering extracellular pH values from 7.35 to 6.0 showed comparable current reductions in neurons from wildtype and K2P9.1-/- mice (68.31 +/- 9.80% and 69.92 +/- 11.65%, respectively). These results could be translated in an in vivo model of cerebral ischemia where infarct volumes and functional outcomes showed a none significant tendency towards smaller infarct volumes in K2P9.1-/- animals compared to wildtype mice 24 hours after 60 min of tMCAO induction (60.50 +/- 17.31 mm3 and 47.10 +/- 19.26 mm3, respectively). CONCLUSIONS: Together with findings from earlier studies on K2P2.1-/- and K2P3.1-/- mice, the results of the present study on K2P9.1-/- mice indicate a differential contribution of K2P channel subtypes to the diverse and complex in vivo effects in rodent models of cerebral ischemia.
Background: Thrombus formation is a key step in the pathophysiology of acute ischemic stroke and results from the activation of the coagulation cascade. Thrombin plays a central role in this coagulation system and contributes to thrombus stability via activation of thrombin-activatable fibrinolysis inhibitor (TAFIa). TAFIa counteracts endogenous fibrinolysis at different stages and elevated TAFI levels are a risk factor for thrombotic events including ischemic stroke. Although substantial in vitro data on the influence of TAFI on the coagulation-fibrinolysis-system exist, investigations on the consequences of TAFI inhibition in animal models of cerebral ischemia are still lacking. In the present study we analyzed stroke development and post stroke functional outcome in TAFI-/- mice. Methodology/Principal Findings: TAFI-/- mice and wild-type controls were subjected to 60 min transient middle cerebral artery occlusion (tMCAO) using the intraluminal filament method. After 24 hours, functional outcome scores were assessed and infarct volumes weremeasured from 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained brain slices. Hematoxylin and eosin (H&E) staining was used to estimate the extent of neuronal cell damage. Thrombus formation within the infarcted brain areas was analyzed by immunoblot. Infarct volumes and functional outcomes did not significantly differ between TAFI-/- mice and controls (p.0.05). Histology revealed extensive ischemic neuronal damage regularly including the cortex and the basal ganglia in both groups. TAFI deficiency also had no influence on intracerebral fibrin(ogen) formation after tMCAO. Conclusion: Our study shows that TAFI does not play a major role for thrombus formation and neuronal degeneration after ischemic brain challenge.
NKG2D is an activating receptor on T cells, which has been implicated in the pathogenesis of autoimmune diseases. T cells are critically involved in idiopathic inflammatory myopathies (IIM) and have been proposed as specific therapeutic targets. However, the mechanisms underlying T cell-mediated progressive muscle destruction in IIM remain to be elucidated. We here determined the involvement of the NKG2D - IL-15 signaling pathway. Primary human myoblasts expressed NKG2D ligands, which were further upregulated upon inflammatory stimuli. In parallel, shedding of the soluble NKG2D ligand MICA (sMICA) decreased upon inflammation potentially diminishing inhibition of NKG2D signaling. Membrane-related expression of IL-15 by myoblasts induced differentiation of naive CD8\(^+\) T cells into highly activated, cytotoxic \(CD8^+NKG2D^{high}\) T cells demonstrating NKG2D-dependent lysis of myoblasts in vitro. \(CD8^+NKG2D^{high}\) T cell frequencies were increased in the peripheral blood of polymyositis (PM) patients and correlated with serum creatinine kinase concentrations, while serum sMICA levels were not significantly changed. In muscle biopsy specimens from PM patients expression of the NKG2D ligand MICA/B was upregulated, IL-15 was expressed by muscle cells, CD68\(^+\) macrophages as well as CD4\(^+\) T cells, and \(CD8^+NKG2D^+\) cells were frequently detected within inflammatory infiltrates arguing for a local signaling circuit in the inflammatory muscle milieu. In conclusion, the NKG2D - IL-15 signaling pathway contributes to progressive muscle destruction in IIM potentially opening new therapeutic avenues.
Background and Purpose
Ischemic stroke provokes severe brain damage and remains a predominant disease in industrialized countries. The coagulation factor XII (FXII)-driven contact activation system plays a central, but not yet fully defined pathogenic role in stroke development. Here, we investigated the efficacy of the FXIIa inhibitor rHA-Infestin-4 in a rat model of ischemic stroke using both a prophylactic and a therapeutic approach.
Methods
For prophylactic treatment, animals were treated intravenously with 100 mg/kg rHA-Infestin-4 or an equal volume of saline 15 min prior to transient middle cerebral artery occlusion (tMCAO) of 90 min. For therapeutic treatment, 100 mg/kg rHA-Infestin-4, or an equal volume of saline, was administered directly after the start of reperfusion. At 24 h after tMCAO, rats were tested for neurological deficits and blood was drawn for coagulation assays. Finally, brains were removed and analyzed for infarct area and edema formation.
Results
Within prophylactic rHA-Infestin-4 treatment, infarct areas and brain edema formation were reduced accompanied by better neurological scores and survival compared to controls. Following therapeutic treatment, neurological outcome and survival were still improved although overall effects were less pronounced compared to prophylaxis.
Conclusions
With regard to the central role of the FXII-driven contact activation system in ischemic stroke, inhibition of FXIIa may represent a new and promising treatment approach to prevent cerebral ischemia/reperfusion injury.
B cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patients without this reactivity. Only in patients that classified as B cell responders, there was a significant positive correlation between treatment duration and the time since last relapse in our study. This correlation was GA-specific because it was absent in a control group that consisted of interferon-\(\beta\) (IFN-\(\beta\))-treated RRMS patients (n = 23). These data suggest that GA has an effect on brain-reactive B cells in a subset of patients and that only this subset benefits from treatment. The detection of brain-reactive B cells is likely to be a suitable tool to identify drug responders.
As recently reviewed, 1026 neuroprotective drug candidates in stroke research have all failed on their road towards validation and clinical translation, reasons being quality issues in preclinical research and publication bias. Quality control guidelines for preclinical stroke studies have now been established. However, sufficient understanding of the underlying mechanisms of neuronal death after stroke that could be possibly translated into new therapies is lacking. One exception is the hypothesis that cellular death is mediated by oxidative stress. Oxidative stress is defined as an excess of reactive oxygen species (ROS) derived from different possible enzymatic sources. Among these, NADPH oxidases (NOX1-5) stand out as they represent the only known enzyme family that has no other function than to produce ROS. Based on data from different NOX knockout mouse models in ischemic stroke, the most relevant isoform appears to be NOX4. Here we discuss the state-of-the-art of this target with respect to stroke and open questions that need to be addressed on the path towards clinical translation.
Objective:
Traumatic brain injury is a major global public health problem for which specific therapeutic interventions are lacking. There is, therefore, a pressing need to identify innovative pathomechanism-based effective therapies for this condition. Thrombus formation in the cerebral microcirculation has been proposed to contribute to secondary brain damage by causing pericontusional ischemia, but previous studies have failed to harness this finding for therapeutic use. The aim of this study was to obtain preclinical evidence supporting the hypothesis that targeting factor XII prevents thrombus formation and has a beneficial effect on outcome after traumatic brain injury.
Methods:
We investigated the impact of genetic deficiency of factor XII and acute inhibition of activated factor XII with a single bolus injection of recombinant human albumin-fused infestin-4 (rHA-Infestin-4) on trauma-induced microvascular thrombus formation and the subsequent outcome in 2 mouse models of traumatic brain injury.
Results:
Our study showed that both genetic deficiency of factor XII and an inhibition of activated factor XII in mice minimize trauma-induced microvascular thrombus formation and improve outcome, as reflected by better motor function, reduced brain lesion volume, and diminished neurodegeneration. Administration of human factor XII in factor XII-deficient mice fully restored injury-induced microvascular thrombus formation and brain damage.
Interpretation:
The robust protective effect of rHA-Infestin-4 points to a novel treatment option that can decrease ischemic injury after traumatic brain injury without increasing bleeding tendencies.
Background:
Inhibition of early platelet adhesion by blockade of glycoprotein-IB (GPIb) protects mice from ischemic stroke. To elucidate underlying mechanisms in-vivo, infarct development was followed by ultra-high field MRI at 17.6 Tesla.
Methods:
Cerebral infarction was induced by transient-middle-cerebral-artery-occlusion (tMCAO) for 1 hour in C57/BL6 control mice (N = 10) and mice treated with 100 mg Fab-fragments of the GPIb blocking antibody p0p/B 1 h after tMCAO (N = 10). To control for the effect of reperfusion, additional mice underwent permanent occlusion and received anti-GPIb treatment (N = 6; pMCAO) or remained without treatment (N = 3; pMCAO). MRI 2 h and 24 h after MCAO measured cerebral-blood-flow (CBF) by continuous arterial-spin labelling, the apparent-diffusion-coefficient (ADC), quantitative-T2 and T2-weighted imaging. All images were registered to a standard mouse brain MRI atlas and statistically analysed voxel-wise, and by cortico-subcortical ROI analysis.
Results:
Anti-GPIb treatment led to a relative increase of postischemic CBF vs. controls in the cortical territory of the MCA (2 h: 44.2 +/- 6.9 ml/100g/min versus 24 h: 60.5 +/- 8.4; p = 0.0012, F((1,18)) = 14.63) after tMCAO. Subcortical CBF 2 h after tMCAO was higher in anti-GPIb treated animals (45.3 +/- 5.9 vs. controls: 33.6 +/- 4.3; p = 0.04). In both regions, CBF findings were clearly related to a lower probability of infarction (Cortex/Subcortex of treated group: 35%/65% vs. controls: 95%/100%) and improved quantitative-T2 and ADC. After pMCAO, anti-GPIb treated mice developed similar infarcts preceded by severe irreversible hypoperfusion as controls after tMCAO indicating dependency of stroke protection on reperfusion.
Conclusion:
Blockade of platelet adhesion by anti-GPIb-Fab-fragments results in substantially improved CBF early during reperfusion. This finding was in exact spatial correspondence with the prevention of cerebral infarction and indicates in-vivo an increased patency of the microcirculation. Thus, progression of infarction during early ischemia and reperfusion can be mitigated by anti-platelet treatment.
Traumatic brain injury (TBI) is a major cause of mortality and morbidity worldwide. Despite improvements in acute intensive care, there are currently no specific therapies to ameliorate the effects of TBI. Successful therapeutic strategies for TBI should target multiple pathophysiologic mechanisms that occur at different stages of brain injury. The kallikrein-kinin system is a promising therapeutic target for TBI as it mediates key pathologic events of traumatic brain damage, such as edema formation, inflammation, and thrombosis. Selective and specific kinin receptor antagonists and inhibitors of plasma kallikrein and coagulation factor XII have been developed, and have already shown therapeutic efficacy in animal models of stroke and TBI. However, conflicting preclinical evaluation, as well as limited and inconclusive data from clinical trials in TBI, suggests that caution should be taken before transferring observations made in animals to humans. This review summarizes current evidence on the pathologic significance of the kallikrein-kinin system during TBI in animal models and, where available, the experimental findings are compared with human data.